89bio Inc

89bio — Technical Presentation (March 2023)

24 slides from 89bio's technical presentation, Mar 22, 2023

  1. Slide 1: Pegozafermin Phase 2b (ENLIVEN) Topline Results in NASH

    Powerful Science Meaningful Medicines Changing Lives Pegozafermin Phase 2b (ENLIVEN) Topline Results in Nonalcoholic Steatohepatitis (NASH) Nasdaq: ETNB Exhibit 99.2

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of his

  3. Slide 3: Pegozafermin – A Potentially Differentiated and Foundational NASH Drug

    Pegozafermin – A Potentially Differentiated and Foundational NASH Drug Statistically Significant Results on Fibrosis Improvement and NASH Resolution Fibrosis improvement – 3.5x and NASH resolution – 12-14x placebo rate Favorable Safety and Tolerability Profile Significant Results with Weekly and Eve

  4. Slide 4: ENLIVEN Trial Design

    ENLIVEN Trial Design F2-F3 NASH; NAS ≥4 PRIMARY ANALYSIS POPULATION MRI-PDFF Liver Biopsy B SCREENING RANDOMIZATION B B Placebo (QW or Q2W) Pegozafermin 15mg QW Pegozafermin 30mg QW Pegozafermin 44mg Q2W PLACEBO Q2W Pegozafermin 15mg QW Pegozafermin 30mg QW Pegozafermin 44mg Q2W MAIN STUDY (24 weeks

  5. Slide 5: Rigorous Biopsy Reading Method Designed to Identify Drug Effect

    Rigorous Biopsy Reading Method Designed to Identify Drug Effect All biopsies scored independently Pathologist #1 Score recorded 3 of 3 agree on score (full agreement) 2 of 3 agree on score (mode) Median or Consensus phone call Score recorded Score recorded Pathologist #2 Pathologist #3 >95% in ENLIV

  6. Slide 6: Patient Disposition and Analysis Sets

    Patient Disposition and Analysis Sets Analysis Sets were prospectively defined Completer Analysis Set = FAS subjects with biopsies at both baseline and Week 24 (n=164). MRI-PDFF Analysis Set = all subjects in FAS with baseline and at least one post-baseline MRI-PDFF assessment (n=181). RANDOMIZED N=

  7. Slide 7: Baseline Characteristics Well Balanced Across Dose Groups

    Baseline Characteristics Well Balanced Across Dose Groups Source: Randomized Analysis Set. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; NAFLD, nonalcoholic fatty liver disease; PRO-C3, N-terminal type III collagen propeptide; VCTE, Vibration-controlled transi

  8. Slide 8: Pegozafermin Demonstrated Statistical Significance on Fibrosis Improvement

    p=0.1 Pegozafermin Demonstrated Statistical Significance on Fibrosis Improvement with Weekly and Every-Two-Week Dosing Fibrosis Improvement Without Worsening of NASH at Week 24 * Relative risk presented is calculated by dividing the drug response by placebo response. Relative risk calculated using s

  9. Slide 9: Pre-Specified Additional Analyses Confirm Robustness of Primary Efficacy Results

    Pre-Specified Additional Analyses Confirm Robustness of Primary Efficacy Results Source: FAS for ITT and Completer Analysis Set 30mg QW 44mg Q2W Completer Analysis Set (n=164) Effect Size (placebo-adjusted) 19% 20% p-value 0.009 0.008 Intent-to-treat (ITT; missing data = non-responder); (n=192) Effe

  10. Slide 10: Clinical Data in Pre-Cirrhotic Patients: Fibrosis Improvement Cross-Trial Comparison

    p=0.008 p=0.008 p=ns p<0.0001 p=0.0002 p=ns p=0.04 p<0.001 p<0.05 Resmetirom2 Phase 3 | 52 weeks Clinical Data in Pre-Cirrhotic Patients ≥1 Stage Fibrosis Improvement with No Worsening of NASH (placebo-adjusted) *Drug response as multiple of placebo response is calculated by dividing drug response b

  11. Slide 11: Descriptive Analysis Data of Cirrhotic (F4) Patients from ENLIVEN

    Descriptive Analysis Data of Cirrhotic (F4) Patients from ENLIVEN Fibrosis Improvement Without Worsening of NASH1 at Week 24 12/14 F4 patients enrolled in ENLIVEN had follow-up biopsies at week 24 n=1 n=11 5/11 patients had fibrosis improvement without worsening of NASH1 1Improvement in liver fibros

  12. Slide 12: NASH Resolution Without Worsening of Fibrosis

    NASH Resolution Without Worsening of Fibrosis at Week 24 Pegozafermin Demonstrated Statistical Significance on NASH Resolution at All Doses p=0.0009 p=0.0005 p<0.0001 n=61 n=66 n=51 n=14 35% 21% 24% Relative Risk* 1.0 18.8 11.8 13.5 * Relative risk presented is calculated by dividing the drug respon

  13. Slide 13: Pre-Specified Additional Analyses Confirm Robustness of Primary Efficacy Results

    Pre-Specified Additional Analyses Confirm Robustness of Primary Efficacy Results Source: FAS for ITT and Completer Analysis Set 15% 19% 20% 30mg QW 44mg Q2W Completer Analysis Set (n=164) Effect Size (placebo-adjusted) 21% 24% p-value 0.0009 0.0004 ITT (missing data = non-responder); (n=192) Effect

  14. Slide 14: Clinical Data in Pre-Cirrhotic Patients: NASH Resolution Cross-Trial Comparison

    Drug response as multiple of placebo response* Efruxifermin Clinical Data in Pre-Cirrhotic Patients NASH Resolution with No Worsening of Fibrosis * Drug response as multiple of placebo response is calculated by dividing drug response by placebo response 1 Results same for Completer Analysis Set 2 NA

  15. Slide 15: ≥2-point NAS Improvement and No Worsening of Fibrosis

    ≥2-point NAS Improvement and no Worsening of Fibrosis1 at Week 24 Pegozafermin Demonstrated Statistical Significance on ≥2-point NAS Improvement 1 Full Analysis Set. Analysis via Cochran-Mantel-Haenszel (CMH) test stratified by T2DM status (yes vs. no) and fibrosis stage (F2 vs. F3) ***p<0.001 versu

  16. Slide 16: Robust Liver Fat Reduction with High Responder Rates by MRI-PDFF

    Pegozafermin Demonstrated Robust Liver Fat Reduction with High Responder Rates by MRI-PDFF at Week 24 Mean Relative Reduction in Liver Fat vs Baseline1 at Week 24 n=48 n=44 n=33 Placebo (n=48) 30mg QW (n=44) 44mg Q2W (n=33) 13% 66%*** 67%*** Proportion of Patients Achieving ≥50% Reductions in Liver

  17. Slide 17: Significant Improvements in Markers of Liver Injury (ALT and AST)

    Pegozafermin Demonstrated Significant Improvements in Markers of Liver Injury (ALT and AST) Source: Full Analysis Set: Analysis via mixed model with repeated measure (MMRM). Data presented as LS Means. ***p<0.001 versus placebo. Mean Relative Reduction in ALT vs Baseline at Week 24 Mean Relative Red

  18. Slide 18: Significant Reductions in Non-Invasive Markers of Hepatic Inflammation and Fibrosis

    Pegozafermin Demonstrated Significant Reductions in Non-Invasive Markers (NITs) of Hepatic Inflammation and Fibrosis cT1 Responders at Week 24 n=61 n=66 n=51 n=61 n=66 n=51 VCTE Absolute Change from Baseline at Week 24 (kPa) n=61 n=66 n=51 PRO-C3 Percent Change from Baseline at Week 24 Placebo-adjus

  19. Slide 19: Pegozafermin Demonstrated Meaningful Reductions in HbA1c

    Change in HbA1c from Baseline at Week 24 Pegozafermin Demonstrated Meaningful Reductions in HbA1c Source: Full Analysis Set for either overall population or FAS with baseline HbA1c ≥6.5%. Analysis via MMRM. Baseline HbA1c ≥6.5% n=31 n=32 n=25 Total Population n=61 n=66 n=51 *p<0.05, **p<0.01 versus

  20. Slide 20: Pegozafermin Demonstrated Meaningful Changes in Serum Lipids

    Pegozafermin Demonstrated Meaningful Changes in Serum Lipids Source: Full Analysis Set. Analysis via van Eltren Test for triglycerides (reported as median) and mixed model with repeated measure (MMRM). Subjects with missing week 24 triglycerides are excluded from the non-parametric analysis. Non-HDL

  21. Slide 21: Pegozafermin Was Well Tolerated Across Doses

    Pegozafermin Was Well Tolerated Across Doses Low incidence of treatment-related TEAEs Preferred Term Placebo (n=69) 15mg QW (n=21) 30mg QW (n=72) 44mg Q2W (n=57) Diarrhea 3% 24% 17% 9% Nausea 1% 14% 21% 18% Injection site erythema 3% 14% 14% 5% Injection site rash 1% 0 10% 4% Increased appetite 0 10

  22. Slide 22: Pegozafermin – A Potentially Differentiated and Foundational NASH Therapy

    PEGOZAFERMIN Pegozafermin – A Potentially Differentiated and Foundational NASH Therapy FGF21 - promising mechanism Significant histology changes (Fibrosis improvement and NASH resolution) Broad metabolic benefits Favorable Safety and Tolerability profile Every-two-week dosing Liquid formulation pref

  23. Slide 23: Appendix

    APPENDIX

  24. Slide 24: Over 60% of T2D Patients Prefer Every-Two-Week Injections

    Over 60% of T2D Patients Prefer or Strongly Prefer Every-Two-Week Injections 63% Prefer or Strongly Prefer Preference of Every-Two-Week Injections Over Weekly Injections Every-two-week dosing provides opportunity for physicians to optimize therapy to patient preference Compliance is important in tre

89bio — Technical Presentation (March 2023) on 6ix